ECTRIMS eLearning

Survival and mortality in multiple sclerosis: a 60-year longitudinal population study
Author(s): ,
H.M Lunde
Affiliations:
Department of Clinical Medicine, KG Jebsen MS Research Centre, University of Bergen
,
J Assmuss
Affiliations:
Competence Centre for Clinical Research
,
K.-M Myhr
Affiliations:
Department of Neurology, Haukeland University Hospital, The Norwegian Multiple Sclerosis Centre;Department of Clinical Medicine, KG Jebsen MS Research Centre, University of Bergen,Norway, Bergen, Norway
,
L Bø
Affiliations:
Department of Neurology, Haukeland University Hospital, The Norwegian Multiple Sclerosis Centre;Department of Clinical Medicine, KG Jebsen MS Research Centre, University of Bergen,Norway, Bergen, Norway
N Grytten
Affiliations:
Department of Clinical Medicine, KG Jebsen MS Research Centre, University of Bergen,Norway, Bergen, Norway
ECTRIMS Learn. Lunde H. 09/15/16; 146144; P303
Hanne Marie Lunde
Hanne Marie Lunde
Contributions
Abstract

Abstract: P303

Type: Poster

Abstract Category: Clinical aspects of MS - Natural course

Introduction: Mortality studies in MS have shown inconsistent results. We aimed to investigate survival, and mortality in a population based multiple sclerosis (MS) cohort.

Methods: The study comprised all incident MS patients (N=1388) with onset during 1953-2012 in Hordaland County, Western Norway. Patient information was obtained from patient records at Haukeland University Hospital and linked to the Norwegian Causes of Death (COD) registry. Survival and patient characteristics (sex, age, disease course) were estimated by Kaplan-Meier analyses from birth and from disease onset. Mortality in MS relative to the general population was examined using standardized mortality ratio (SMR).

Results: Of 1388 patients, 291 had deceased, mainly of MS (56.4 %). Median survival age was 74.7 years in MS and 81.8 years in the general population (p< 0.001). Women had longer median life expectancy (77.2 years) than men (72.2 years, p=0.003) and patients with relapsing remitting MS (RRMS) survived longer ( 77.8 years) than patients with primary progressive MS (PPMS) (71.4 years, p< 0.001). Median survival from disease onset was longer in RRMS (42.8 years) than in PPMS (25.5 years, p< 0.001). Overall SMR was 2.71 ( 95 % CI: 2.4, 3.0); in RRMS 2.4 ( 95 % CI: 2.1, 2.7) and 3.9 (95 % CI: 3.1, 4.7) in PPMS. SMR from disease onset during 1953-1974 was 3.1 (95 % CI: 2.7, 3.6), during 1975-1996, 2.6 (95 % CI: 2.2, 3.1) and during 1997-2012: 0.7 (95 % CI: 0.3,1.5).

Conclusion: The longest follow-up period of 60 years on survival and mortality in MS is here reported. MS had a 7- year lower median survival age than the general population. Risk of death was almost threefold higher in MS relative to the general population. However, an encouraging decrease in mortality was observed during the last 40 years.

Disclosure:

Hanne Marie Bøe Lunde: nothing to disclose

Jorg Assmuss: nothing to disclose

Kjell-Morten Myhr: nothing to disclose

Lars Bø: nothing to disclose

Nina Grytten: nothing to disclose

Abstract: P303

Type: Poster

Abstract Category: Clinical aspects of MS - Natural course

Introduction: Mortality studies in MS have shown inconsistent results. We aimed to investigate survival, and mortality in a population based multiple sclerosis (MS) cohort.

Methods: The study comprised all incident MS patients (N=1388) with onset during 1953-2012 in Hordaland County, Western Norway. Patient information was obtained from patient records at Haukeland University Hospital and linked to the Norwegian Causes of Death (COD) registry. Survival and patient characteristics (sex, age, disease course) were estimated by Kaplan-Meier analyses from birth and from disease onset. Mortality in MS relative to the general population was examined using standardized mortality ratio (SMR).

Results: Of 1388 patients, 291 had deceased, mainly of MS (56.4 %). Median survival age was 74.7 years in MS and 81.8 years in the general population (p< 0.001). Women had longer median life expectancy (77.2 years) than men (72.2 years, p=0.003) and patients with relapsing remitting MS (RRMS) survived longer ( 77.8 years) than patients with primary progressive MS (PPMS) (71.4 years, p< 0.001). Median survival from disease onset was longer in RRMS (42.8 years) than in PPMS (25.5 years, p< 0.001). Overall SMR was 2.71 ( 95 % CI: 2.4, 3.0); in RRMS 2.4 ( 95 % CI: 2.1, 2.7) and 3.9 (95 % CI: 3.1, 4.7) in PPMS. SMR from disease onset during 1953-1974 was 3.1 (95 % CI: 2.7, 3.6), during 1975-1996, 2.6 (95 % CI: 2.2, 3.1) and during 1997-2012: 0.7 (95 % CI: 0.3,1.5).

Conclusion: The longest follow-up period of 60 years on survival and mortality in MS is here reported. MS had a 7- year lower median survival age than the general population. Risk of death was almost threefold higher in MS relative to the general population. However, an encouraging decrease in mortality was observed during the last 40 years.

Disclosure:

Hanne Marie Bøe Lunde: nothing to disclose

Jorg Assmuss: nothing to disclose

Kjell-Morten Myhr: nothing to disclose

Lars Bø: nothing to disclose

Nina Grytten: nothing to disclose

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies